Stockhead’s Ashtyn Hiron sits down with Race Oncology (ASX:RAC) CEO Daniel Tillett to close the books on 2023 and gain a sneak peek into what’s around the corner.

The clinical stage biopharmaceutical company makes drugs that are designed to treat cancer better with its lead asset, bisantrene (RC220) , currently in Phase II trials for Acute Myeloid Leukemia.

“We’re about to start a series of new trials towards the second half of 2024 for solid tumours so basically all other cancers,” Tillett says.

Tune in to hear what’s coming up for Race Oncology in 2024.